AGE实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Mar 2024 @ 03:59):

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States...

Stats
今日成交量	3 681.00
平均成交量	3 980.00
市值	27.76M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0200
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-08	Mintz Steven	Sell	0	Common Stock, $0.0001 par value
2024-01-08	Mintz Steven	Sell	63 756	Option to Purchase Common Stock
2023-08-09	Renondin Jean-christophe	Sell	25 821	Option to Purchase Common Stock
2023-04-25	Juvenescence Ltd	Buy	756 429	Warrant to Purchase Common Stock
2023-03-14	Juvenescence Ltd	Sell	16 447 500	Common Stock

INSIDER POWER
-63.36
Last 97 transactions
Buy: 22 648 571 \| Sell: 17 037 050

AgeX Therapeutics Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AgeX Therapeutics Inc 财务报表

Annual	2023
营收:	$142 000
毛利润:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2023
营收:	$142 000
毛利润:	$-29 000.00 (-20.42 %)
EPS:	$-13.72

FY	2022
营收:	$34 000.00
毛利润:	$21 000.00 (61.76 %)
EPS:	$-9.89

FY	2021
营收:	$144 000
毛利润:	$125 000 (86.81 %)
EPS:	$-0.230

Financial Reports:

No articles found.

AgeX Therapeutics Inc

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550, a gene delivery technology. The company has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. AgeX Therapeutics, Inc. was incorporated in 2017 and is based in Alameda, California.